Developing drugs for neurodegeneration and other diseases in academia, industry and in-between

Add to your list(s) Download to your calendar using vCal

• John Skidmore, Alzheimer’s Research UK Cambridge Drug Discovery Institute
• Wednesday 21 February 2018, 10:30-11:30
• Department of Chemistry, Cambridge, Unilever lecture theatre.

If you have a question about this talk, please contact Patrick Flagmeier.

Over recent decades, medicinal chemists have proven to be very efficient at finding small molecules to modulate the activity of enzyme and receptor targets but this has not always led to the development of new drugs. Drawing on examples from industry, academia and the not-for-profit sector, ways in which this gap can be bridged will be explored. Firstly, the importance of expanding the range of druggable targets will be discussed using the example of RAD51 -BRCA2 protein-protein interaction inhibitors. Secondly, the challenge of identifying druggable targets to drive a reduction in the level of the misfolded proteins thought to cause many neurodegenerative diseases will be explored, using examples from the Alzheimer’s Research UK Cambridge Drug Discovery Institute.

This talk is part of the Biophysical Seminars series.

This talk is included in these lists:

• All Talks (aka the CURE list)
• Biophysical Seminar Series 2016/17
• Biophysical Seminars
• Department of Chemistry
• Department of Chemistry, Cambridge, Unilever lecture theatre
• Featured lists
• School of Physical Sciences

Note that ex-directory lists are not shown.